Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.56 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225868 | 0.87 | VCAM1 (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL3619380 | 0.87 | SLC25A1 (0.67) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL11752812 | 0.87 | VCAM1 (0.60) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL5228187 | 0.85 | VCAM1 (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL5225915 | 0.85 | VCAM1 (0.64) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL24215474 | 0.84 | MEN1 (0.70) | VCAM1DNMT1DNMT3ASLC25A1MEN1 | |
| SCHEMBL30515749 | 0.84 | MEN1 (0.70) | VCAM1DNMT1DNMT3ASLC25A1MEN1 | |
| SCHEMBL28746841 | 0.84 | ALDH1A1 (0.60) | VCAM1DNMT1DNMT3ASLC25A1HSPD1 | |
| SCHEMBL14434547 | 0.83 | MAPT (0.65) | ALDH1A1TSHRCYP1A2CYP3A4PKM | |
| SCHEMBL8248683 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TSHRCYP1A2CYP3A4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| CN-1329382-C | Novel arylsusfonamide compounds for treatment of obesity, type II diabetes and CNS-disorders | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| CN-1531531-A | Novel arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | VCAM1 3816/4885DNMT1 4144/4885DNMT3A 4655/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | VCAM1 3816/4885DNMT1 4144/4885DNMT3A 4655/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | VCAM1 4442/4885DNMT1 4229/4885DNMT3A 4675/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | VCAM1 4442/4885DNMT1 4229/4885DNMT3A 4675/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | VCAM1 4442/4885DNMT1 4229/4885DNMT3A 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.